Themis Medicare Share: Bull Case vs Bear Case for 2026

The Themis Medicare bull case is under the spotlight as investors weigh Themis Medicare's recent price action against its underlying fundamentals. The stock trades at Rs 121.37, against a 52 week high of Rs 148.00 and a 52 week low of Rs 64.95, leaving room for both the Themis Medicare bull case and the Themis Medicare bear case to find support in the data.

Themis Medicare operates in the Pharmaceuticals space, and its return on equity of 0.42 percent and debt to equity ratio of 0.25 form part of the fundamental picture. This article lays out the full Themis Medicare bull case and bear case, the data behind each scenario, and the catalysts that could tip the balance one way or the other.

Click Here – Get Free Investment Predictions

Themis Medicare Company Overview

Themis Medicare is a Mumbai-based pharmaceutical company making formulations and active ingredients for domestic and export markets. Its profits have fallen for several years in a row, which makes the recent rebound in quarterly earnings the central question for the stock.

Metric	Value
NSE Ticker	Themis Medicare (THEMISMED)
Sector	Pharmaceuticals
CMP	Rs 121.37
52 Week High	Rs 148.00
52 Week Low	Rs 64.95
Market Cap	Rs 1,078 Crore
P/E Ratio	26.98 (Industry PE 38.42)
Industry P/E	38.42
Return on Equity	0.42 percent
Debt to Equity	0.25

Themis Medicare reports earnings per share of Rs 4.34, a book value of Rs 39.74 per share and a dividend yield of 0.43 percent at the current price. These fundamentals form the base data behind the Themis Medicare bull case discussed below, and they are worth keeping in mind while weighing the Themis Medicare bull case against the risks in the bear case.

The Themis Medicare Bull Case

Big Profit Swing In The Latest Quarter

Net profit for the June 2026 quarter was Rs 24.61 crore, against a loss of Rs 14.22 crore in the June 2025 quarter. That completes three straight profitable quarters after two loss-making ones, which is the best run in more than a year.

Stock Has Nearly Doubled From The Low

Shares have climbed from a 52 week low of Rs 64.95 to Rs 121.37 and were up nearly 4 percent in the latest session on heavy volume. The market is clearly looking through the weak past year.

Valuation Below The Sector

A price to earnings ratio of 26.98 compared with the pharma industry average of 38.42 suggests the stock is not expensive if earnings hold at the recent level.

Reasonable Leverage

A debt to equity ratio of 0.25 leaves the balance sheet manageable while the company rebuilds profitability.

Taken together, the strengths above, including big profit swing in the latest quarter, stock has nearly doubled from the low and valuation below the sector, form the core of the Themis Medicare bull case for the stock. Investors building the Themis Medicare bull case into their own thesis should weigh each of these strengths against the risks discussed next.

The Themis Medicare Bear Case

Profits Down For Five Years

Annual net profit has fallen from Rs 72.88 crore in FY22 to just Rs 1.14 crore in FY26, and revenue dropped to Rs 351.6 crore in FY26 from Rs 410.18 crore in FY25. The long decline is why the return on equity is only 0.42 percent.

Quality Of The Recent Profit Is Unclear

The June 2026 operating margin shows as roughly 51 percent, far above the company's history, and profit was about 28 percent of revenue. That pattern often points to one-off gains, so the quarter may overstate the earning power of the core business.

Sharp Pullback Toward Oversold

An RSI of 29.97 shows the stock has been under heavy selling recently despite today's bounce, and it is well below the 52 week high of Rs 148.00.

Falling Revenue

June 2026 revenue of Rs 87.95 crore was lower than Rs 98.76 crore a year earlier. A profit recovery without sales growth is harder to sustain.

Weighed against the Themis Medicare bull case, risks such as profits down for five years, quality of the recent profit is unclear and sharp pullback toward oversold are what could keep the stock anchored closer to its recent lows.

Themis Medicare Bull vs Bear Scenario Table

Scenario	Reference Price Level	Key Driver
Bull Case	Retest of 52 week high, Rs 148.00	Strengths outlined above play out and sentiment improves
Current Price	Rs 121.37	Present market price as of 28 Sep 2026
Bear Case	Retest of 52 week low, Rs 64.95	Risks outlined above dominate and sentiment weakens

Using the stock's own 52 week trading range as the reference band keeps both the Themis Medicare bull case and the bear case anchored to real, observed price levels rather than a speculative external forecast.

What Could Tip the Balance Between the Bull and Bear Case

The single most useful thing for Themis Medicare investors to check is how much of the June 2026 profit came from one-off items. If the company shows that operating profit can stay well above the levels of FY26 while revenue stabilises near Rs 90 crore a quarter, the bull case gains real weight. If profit falls back toward zero in the next quarter, the recent rally could unwind.

Broader trends in the pharmaceuticals space and overall market risk appetite are the other variables worth tracking through the rest of 2026.

How to Invest in Themis Medicare

Investors weighing the Themis Medicare bull case against the bear case can use the Univest Screener to check live fundamentals, valuation ratios and peer comparisons before making a decision.

Start by opening a demat and trading account with a SEBI registered broker if you do not already have one active.

Review Themis Medicare's quarterly results and sector trends to see which case the latest data supports, since fresh numbers can quickly shift the balance of the Themis Medicare bull case versus the bear case.

Weigh the Themis Medicare bull case upside against the bear case downside relative to the current market price to gauge the risk to reward on offer.

Size any position according to your own risk tolerance, since both scenarios discussed here are illustrative and not guaranteed outcomes.

Keeping the Themis Medicare bull case in view as each new quarterly result arrives is a sensible habit for anyone tracking this stock.

Any fresh company filing, order announcement or sector data point can quickly change how strong the Themis Medicare bull case looks.

Comparing the Themis Medicare bull case against the bear case after every earnings release is the simplest way to stay grounded in the numbers.

Readers who follow the Themis Medicare bull case should also track the stock's own 52 week range, since both cases are anchored to it.

The Themis Medicare bull case is a framework for thinking about the stock, not a forecast, and it should be revisited as the data changes.

Whether the Themis Medicare bull case strengthens or fades will depend far more on reported numbers than on short-term price moves.

A patient reading of the Themis Medicare bull case alongside the risks above gives a fuller picture than either case does alone.

New investors often find it useful to write down the Themis Medicare bull case and the bear case in their own words before deciding.

Keeping the Themis Medicare bull case in view as each new quarterly result arrives is a sensible habit for anyone tracking this stock.

Any fresh company filing, order announcement or sector data point can quickly change how strong the Themis Medicare bull case looks.

Conclusion

The Themis Medicare bull case rests on strengths such as big profit swing in the latest quarter, stock has nearly doubled from the low and valuation below the sector playing out as earnings and sector conditions evolve, while the bear case reflects risks such as profits down for five years, quality of the recent profit is unclear and sharp pullback toward oversold that could keep the stock anchored closer to its 52 week low. Whether the Themis Medicare bull case or the bear case plays out will likely become clearer over the next couple of quarters of results and sector data. Investors who track the Themis Medicare bull case closely alongside the bear case risks will be better placed to judge which scenario is actually unfolding.

Download the Univest iOS App or Univest Android App to track Themis Medicare live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Themis Medicare Bull Case vs Bear Case

What is the Themis Medicare bull case for 2026?

Ans. The Themis Medicare bull case for 2026 is built on strengths such as big profit swing in the latest quarter, stock has nearly doubled from the low and valuation below the sector, with the stock able to retest its 52 week high of Rs 148.00 if these strengths continue to play out.

What is the Themis Medicare bear case for 2026?

Ans. The Themis Medicare bear case for 2026 centres on risks such as profits down for five years, quality of the recent profit is unclear and sharp pullback toward oversold, with the stock at risk of retesting its 52 week low of Rs 64.95 if these risks dominate.

Should I buy Themis Medicare share now?

Ans. Themis Medicare trades at Rs 121.37, and whether it fits your portfolio depends on how you weigh the Themis Medicare bull case against the bear case risks discussed in this article, ideally after confirming with a SEBI registered financial advisor.

What are the key risks in the Themis Medicare bear case?

Ans. The key risks in the Themis Medicare bear case include profits down for five years, quality of the recent profit is unclear and sharp pullback toward oversold.

What are the main catalysts for the Themis Medicare bull case?

Ans. The main catalysts for the Themis Medicare bull case include big profit swing in the latest quarter, stock has nearly doubled from the low and valuation below the sector.

Why did Themis Medicare profit jump in June 2026?

Ans. Net profit was Rs 24.61 crore in the June 2026 quarter against a loss of Rs 14.22 crore a year earlier. The operating margin of about 51 percent is far above normal for the company, which suggests the quarter may include one-off items.

Where can I track Themis Medicare share price live?

Ans. You can track Themis Medicare share price live on the Univest Screener, which shows CMP, volume, valuation ratios and other fundamentals updated through the trading session.

What is the 52 week high and low of Themis Medicare?

Ans. The 52 week high of Themis Medicare is Rs 148.00 and the 52 week low is Rs 64.95, with the stock currently trading at Rs 121.37.

How can I buy Themis Medicare shares?

Ans. You can buy Themis Medicare shares through any SEBI registered stockbroker by placing an order on the NSE or BSE during market hours, after reviewing the company's fundamentals and your own investment goals.